Pneumocystis pneumonia in patients with immunobullous dermatoses

Background  Immunobullous dermatoses are usually treated with immunosuppressive agents, which make patients susceptible to pneumocystis pneumonia (PCP). The aim of this study was to evaluate the incidence and clinical characteristics of PCP in patients with immunobullous diseases.

[1]  S. Tyring,et al.  Tropical dermatology: Tropical diseases caused by protozoa. , 2009, Journal of the American Academy of Dermatology.

[2]  E. Calderón,et al.  Prevalence of dihydropteroate synthase mutations in Spanish patients with HIV-associated Pneumocystis pneumonia. , 2009, Diagnostic microbiology and infectious disease.

[3]  M. Anadkat,et al.  Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole. , 2009, Journal of the American Academy of Dermatology.

[4]  R. Guleria,et al.  Study of dihydropteroate synthase (DHPS) gene mutations among isolates of Pneumocystis jiroveci. , 2008, The Indian journal of medical research.

[5]  T. Johkoh,et al.  Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study. , 2008, Internal medicine.

[6]  M. Kimura,et al.  Comparison of trimethoprim–sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease , 2008, Rheumatology International.

[7]  S. Dogra,et al.  Dapsone induced acute photosensitivity dermatitis; a case report and review of literature. , 2007, Leprosy review.

[8]  É. Azoulay,et al.  Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. , 2007, Chest.

[9]  L. Leibovici,et al.  Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. , 2007, Mayo Clinic proceedings.

[10]  A. Limper,et al.  Current insights into the biology and pathogenesis of Pneumocystis pneumonia , 2007, Nature Reviews Microbiology.

[11]  J. Browning,et al.  Medical Pearl: Pneumocystis pneumonia prophylaxis for patients on chronic systemic corticosteroids. , 2006, Journal of the American Academy of Dermatology.

[12]  Jian Li,et al.  Pneumocystis carinii Pneumonia in Patients With Connective Tissue Disease , 2006, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[13]  A. Limper,et al.  Medical progress: Pneumocystis pneumonia , 2004 .

[14]  J. Mclelland,et al.  Pneumocystis carinii pneumonia in a patient on immunosuppressive drugs for pyoderma gangrenosum , 2002, British Journal of Dermatology.

[15]  C. Lacroix,et al.  Analysis of Underlying Diseases and Prognosis Factors Associated with Pneumocystis carinii Pneumonia in Immunocompromised HIV-Negative Patients , 2002, European Journal of Clinical Microbiology and Infectious Diseases.

[16]  K. Sepkowitz.  Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Siu,et al.  Pneumocystis carinii pneumonia in patients receiving immunosuppressive drugs for dermatological diseases , 1999, The British journal of dermatology.

[18]  K. Whyte,et al.  Discrimination against people with HIVinfection and AIDS , 1994, BMJ.

[19]  K. Katsuoka,et al.  Toxic epidermal necrolysis caused by aerosolized pentamidine. , 2009, American Journal of Medicine.